Inversago Pharma

Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy, Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF)

Cb1 receptor,metabolic disorders,diabetes,nash,pulmonary fibrosis,obesity,diabetic kidney disease,and diabetic nephropathy

Inversago pharma operates in the Biotechnology research industry.

Inversago pharma's revenue is 11m - 100m

Inversago pharma has 11 - 50 employees.